Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • Pfizer’s former chemistry whiz debuts Khartis Therapeutics with $95M for thyroid eye disease pill

Pfizer’s former chemistry whiz debuts Khartis Therapeutics with $95M for thyroid eye disease pill

August 12, 2026Posted inBiotechnology

Three years after Robert Hoffman sold XinThera to Gilead, the veteran Pfizer chemist has unveiled his latest venture.

Post navigation

Previous Post
lead-carboxylates-improve-passivation-in-meter-scale-perovskite-solar-modules Lead Carboxylates Improve Passivation in Meter-Scale Perovskite Solar Modules
Next Post
Researchers uncover new control mechanism for decades-old leukemia drug researchers-uncover-new-control-mechanism-for-decades-old-leukemia-drug

Recent Posts

  • Time-Restricted Eating Linked to Improved Huntington’s Disease Markers
  • Asahi Kasei Introduces VANTIJ® SU-VFC Benchtop Virus-Filtration System
  • GBI Biomanufacturing Set to Launch SmartScale GMP Solutions
  • Model-Free, Pure Component Analysis Could Help Biopharma Cut Costs
  • Nu-Tek Brings Topic of Raw-Material Risk to BPI

Archives

  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • March 2024
  • January 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top